English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Twelve new 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl-4Hquinazolin-3-yl)-urea were synthesized and screened for CNS depressant, sedative-hypnotic and phenobarbitone induced hypnosis potentiation test. Spectroscopic data and elemental analysis were consistent with the newly synthesized compounds. All except H1 and H6 showed more than 40% decrease in locomotor activity after 1 h of compound administration via actophotometer screen. CNS depressant activity screened with the help of forced swim method resulted into some potent compounds. Except for H3, H6 and H7 other tested compounds were found to exhibit potent CNS depressant activity as indicated by increased immobility time. No significant percentage increase in the sleeping time was observed in any of the synthesized compounds evaluated by phenobarbitone induced hypnosis potentiation test. It can be concluded that newly synthesized compounds possessed sedative-hypnotic and CNS depressant activities at a significant level.

Design, synthesis and potential CNS activity of some novel 1-(4-substituted-phenyl)-3-(4-oxo-2-propyl-4H-quinazolin-3-yl)-urea